{"id":15881,"date":"2026-01-05T16:23:12","date_gmt":"2026-01-05T14:23:12","guid":{"rendered":"https:\/\/hqsarms.com\/?p=15881"},"modified":"2026-01-13T14:33:00","modified_gmt":"2026-01-13T12:33:00","slug":"slu-pp-332-full-guide","status":"publish","type":"post","link":"https:\/\/hqsarms.com\/lt\/slu-pp-332-full-guide\/","title":{"rendered":"I\u0161samus SLU-PP-332 vadovas: naujas pratyb\u0173 mimetikas"},"content":{"rendered":"<p class=\"wp-block-paragraph\">\u012esivaizduokite, kad gaunate <strong>pratyb\u0173 nauda<\/strong>: geresn\u0117 i\u0161tverm\u0117, geresn\u0117 med\u017eiag\u0173 apykaita ir geresnis riebal\u0173 deginimas, niekada neimant \u012f rankas hanteli\u0173 ar neapsiaunant b\u0117gimo bateli\u0173. Nors tai gali skamb\u0117ti kaip mokslin\u0117 fantastika, Sent Luiso universiteto mokslininkai nustat\u0117 jungin\u012f, kuris priartina mus prie \u0161ios realyb\u0117s.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Susipa\u017einkite su <strong>SLU-PP-332<\/strong>, naujas junginys, kuris <strong>imituoja fizinio kr\u016bvio poveik\u012f med\u017eiag\u0173 apykaitai.<\/strong> suaktyvindamas energij\u0105 reguliuojan\u010dius organizmo receptorius. Nors \u0161i molekul\u0117 dar tik pradedama tyrin\u0117ti, ji spar\u010diai populiar\u0117ja med\u017eiag\u0173 apykaitos, sen\u0117jimo ir darbingumo didinimo srityse.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">I\u0161siai\u0161kinkime, kas tai yra, kaip tai veikia ir kod\u0117l tai gali b\u016bti svarbu ateinan\u010diais metais.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Kas yra SLU-PP-332?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>SLU-PP-332<\/strong>, kartais vadinamas SLOOP, yra sintetin\u0117 ma\u017ea molekul\u0117, sukurta mokslinink\u0173 <strong>Sent Luiso universitetas (SLU)<\/strong>. Jis veikia kaip <strong>Su estrogenu susij\u0119s receptorius<\/strong> (ERR) agonistas.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">ERR receptoriai atlieka svarb\u0173 vaidmen\u012f mitochondrij\u0173 biogenez\u0117je, oksidaciniame metabolizme ir bendrame energijos suvartojime.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Aktyvuodamas ERR\u03b1\/\u03b3, jis tiesiogiai veikia genus, dalyvaujan\u010dius <strong>energijos production, raumen\u0173 funkcija ir riebal\u0173 apykaita.<\/strong>, kurie yra pagrindiniai \u201cpratimams pana\u0161aus\u201d atsako po\u017eymiai.<\/p>\n\n\n\n<figure class=\"wp-block-image size-medium is-resized\"><img decoding=\"async\" width=\"300\" height=\"124\" src=\"https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure-300x124.png\" alt=\"SLU-PP-332 molekulin\u0117 strukt\u016bra\" class=\"wp-image-15882\" style=\"width:500px\" srcset=\"https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure-300x124.png 300w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure-1024x424.png 1024w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure-768x318.png 768w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure-18x7.png 18w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure-990x410.png 990w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure-441x183.png 441w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure-1320x547.png 1320w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure-600x248.png 600w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure-150x62.png 150w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure.png 1338w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><figcaption class=\"wp-element-caption\">SLU-PP-332 molekulin\u0117 strukt\u016bra<\/figcaption><\/figure>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Kaip veikia SLU-PP-332?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Su estrogenais susij\u0119 receptoriai (ERR) yra <strong>branduoliniai receptoriai na\u0161lai\u010diai<\/strong>, o tai rei\u0161kia, kad j\u0173 nat\u016bral\u016bs ligandai (jei toki\u0173 yra) n\u0117ra galutinai nustatyti. Nepaisant j\u0173 pavadinimo, jie nesieja estrogen\u0173. Vietoj to jie reguliuoja energijos apykait\u0105 audiniuose, pvz. <strong>\u0161irdis, skeleto raumenys ir rudieji riebalai.<\/strong>; visi organai, kuriems reikia daug energijos.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SLU-PP-332 veikia pagal <strong>prisijungimas prie ERR\u03b1 ir ERR\u03b3<\/strong>, skatinantis gen\u0173, susijusi\u0173 su:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mitochondrij\u0173 biogenez\u0117<\/strong><\/li>\n\n\n\n<li><strong>Riebal\u0173 r\u016bg\u0161\u010di\u0173 oksidacija<\/strong><\/li>\n\n\n\n<li><strong>Oksidacinis fosforilinimas<\/strong><\/li>\n\n\n\n<li><strong>Gliukoz\u0117s pasisavinimas ir panaudojimas<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Kitaip tariant, jis liepia j\u016bs\u0173 k\u016bnui elgtis taip, tarsi jis b\u016bt\u0173 <strong>reguliari aerobikos treniruot\u0117.<\/strong>, net kai s\u0117dite ramiai.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Tyrimo rezultatai<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Svarbiame 2023 m. tyrime, kuriam vadovavo SLU mokslininkai, SLU-PP-332 poveikis buvo i\u0161bandytas <strong>s\u0117slios pel\u0117s<\/strong> per kelias savaites. \u0160tai k\u0105 jie nustat\u0117:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>\ud83c\udfc3\u200d\u2642\ufe0f <strong>I\u0161tverm\u0117s didinimas<\/strong>: SLU-PP-332 apdorotos pel\u0117s gal\u0117jo <strong>veikia gerokai ilgiau.<\/strong> b\u0117gimo takeliu, palyginti su negydytomis kontrolin\u0117mis grup\u0117mis, nepaisant to, kad jos nebuvo fizi\u0161kai treniruojamos.<\/li>\n\n\n\n<li>\ud83d\udd0b <strong>Mitochondrij\u0173 gen\u0173 rai\u0161ka<\/strong>: Junginys reguliuoja genus, susijusius su <strong>energijos apykaita<\/strong> skeleto raumenyse, imituojant transkripcijos po\u017eymius, pasteb\u0117tus sportuojan\u010di\u0173 gyv\u016bn\u0173 organizme.<\/li>\n\n\n\n<li>\ud83d\udd25 <strong>Riebal\u0173 panaudojimas<\/strong>: Padid\u0117jo <strong>lipid\u0173 apykaita<\/strong>, o tai rodo, kad pel\u0117s degino daugiau riebal\u0173 kaip degal\u0173.<\/li>\n\n\n\n<li>\ud83e\uddec <strong>N\u0117ra \u0161irdies hipertrofijos<\/strong>: Skirtingai nei kai kurie kiti med\u017eiag\u0173 apykaitos stiprintuvai (pvz., GW501516), SLU-PP-332 nesuk\u0117l\u0117 nepageidaujamo \u0161irdies pertvarkymo, o tai yra teigiamas saugumo po\u017eymis.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">D\u0117l \u0161i\u0173 rezultat\u0173 kai kurie SLU-PP-332 apib\u016bdina kaip <strong>\u201cmolekulinis trumpiausias kelias \u012f ger\u0105 fizin\u0119 form\u0105<\/strong>\u201c, ta\u010diau \u0161is posakis turi kelet\u0105 i\u0161lyg\u0173, kurias aptarsime toliau.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">SLU-PP-332 ir kiti fizinio kr\u016bvio mimetikai<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\u0160iuo metu yra keletas jungini\u0173, kuri\u0173 tikslas \u2013 farmakologin\u0117mis priemon\u0117mis imituoti arba sustiprinti fizinio kr\u016bvio poveik\u012f. Kaip SLU-PP-332 palyginti su kitais fizinio kr\u016bvio mimetikais?<\/p>\n\n\n\n<figure class=\"wp-block-table is-style-stripes\"><table class=\"has-fixed-layout\"><thead><tr><th class=\"has-text-align-left\" data-align=\"left\">Sud\u0117tinis<\/th><th class=\"has-text-align-left\" data-align=\"left\">Tikslin\u0117<\/th><th class=\"has-text-align-left\" data-align=\"left\">Pagrindinis poveikis<\/th><\/tr><\/thead><tbody><tr><td class=\"has-text-align-left\" data-align=\"left\"><strong>SLU-PP-332<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\">ERR\u03b1 \/ ERR\u03b3<\/td><td class=\"has-text-align-left\" data-align=\"left\">Mitochondrij\u0173 biogenez\u0117, i\u0161tverm\u0117<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\"><strong>SR-9009<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\">REV-ERB\u03b1<\/td><td class=\"has-text-align-left\" data-align=\"left\">Cirkadinis ritmas, med\u017eiag\u0173 apykaita<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\"><strong>GW-501516<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\">PPAR\u03b4<\/td><td class=\"has-text-align-left\" data-align=\"left\">Riebal\u0173 deginimas, i\u0161tverm\u0117<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\"><strong>GW-0742<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\">PPAR\u03b4<\/td><td class=\"has-text-align-left\" data-align=\"left\">Riebal\u0173 deginimas, i\u0161tverm\u0117<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\"><strong>AICAR<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\">AMPK<\/td><td class=\"has-text-align-left\" data-align=\"left\">L\u0105steli\u0173 energijos jutiklis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">SLU-PP-332 yra ypa\u010d perspektyvus d\u0117l savo <strong>tiesioginis poveikis genams, susijusiems su energijos apykaita<\/strong>, be netikslinio poveikio ar toksi\u0161kumo, kuris persekiojo kitus mimetikus.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"427\" src=\"https:\/\/hqsarms.com\/wp-content\/uploads\/2026\/01\/SLU-PP-332-benefits-1024x427.jpg\" alt=\"SLU-PP-332 privalumai\" class=\"wp-image-19266\" srcset=\"https:\/\/hqsarms.com\/wp-content\/uploads\/2026\/01\/SLU-PP-332-benefits-1024x427.jpg 1024w, https:\/\/hqsarms.com\/wp-content\/uploads\/2026\/01\/SLU-PP-332-benefits-300x125.jpg 300w, https:\/\/hqsarms.com\/wp-content\/uploads\/2026\/01\/SLU-PP-332-benefits-768x320.jpg 768w, https:\/\/hqsarms.com\/wp-content\/uploads\/2026\/01\/SLU-PP-332-benefits-18x8.jpg 18w, https:\/\/hqsarms.com\/wp-content\/uploads\/2026\/01\/SLU-PP-332-benefits-990x413.jpg 990w, https:\/\/hqsarms.com\/wp-content\/uploads\/2026\/01\/SLU-PP-332-benefits-441x184.jpg 441w, https:\/\/hqsarms.com\/wp-content\/uploads\/2026\/01\/SLU-PP-332-benefits-600x250.jpg 600w, https:\/\/hqsarms.com\/wp-content\/uploads\/2026\/01\/SLU-PP-332-benefits-150x63.jpg 150w, https:\/\/hqsarms.com\/wp-content\/uploads\/2026\/01\/SLU-PP-332-benefits.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Potenciali nauda<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Nors reikia atlikti tyrimus su \u017emon\u0117mis, kad b\u016bt\u0173 galima patvirtinti realaus naudojimo galimybes. <strong>ikiklinikiniai duomenys<\/strong> rodo, kad SLU-PP-332 gali b\u016bti naudingas:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>I\u0161tverm\u0117s gerinimas<\/strong><br>Net ir nesitreniruojant, \u0161is junginys didina raumen\u0173 audinio mitochondrij\u0173 funkcij\u0105 ir aerobin\u012f paj\u0117gum\u0105.<\/li>\n\n\n\n<li><strong>Med\u017eiag\u0173 apykaitos sutrikim\u0173 gydymas<\/strong><br>Tokiems sutrikimams kaip nutukimas, antrojo tipo diabetas ir kepen\u0173 surieb\u0117jimas gali b\u016bti naudingas padid\u0117j\u0119s mitochondrij\u0173 aktyvumas ir pager\u0117jusi riebal\u0173 oksidacija.<\/li>\n\n\n\n<li><strong>Kova su raumen\u0173 i\u0161sekimu<\/strong><br>SLU-PP-332 gali pad\u0117ti i\u0161saugoti raumen\u0173 funkcij\u0105 ir energijos apykait\u0105 tokiomis s\u0105lygomis kaip sen\u0117jimas, v\u0117\u017ein\u0117 kacheksija ar ilgalaikis gul\u0117jimas lovoje.<\/li>\n\n\n\n<li><strong>Ilgaam\u017ei\u0161kumas ir apsauga nuo sen\u0117jimo<\/strong><br>Nors ir sp\u0117jama, bet viskas, kas gerina mitochondrij\u0173 funkcij\u0105, domina ilgaam\u017ei\u0161kumo bendruomen\u0119. Kadangi mitochondrij\u0173 nykimas yra susij\u0119s su sen\u0117jimu, j\u0173 veiklos gerinimas gal\u0117t\u0173 b\u016bti veiksminga intervencija.<\/li>\n<\/ol>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">\u0160alutinis poveikis<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Kiekvienam junginiui, ypa\u010d naujam, b\u016bdingos tam tikros i\u0161lygos. Taigi kokie galimi SLU-PP-332 tr\u016bkumai? Kol kas, <strong>atliekant tyrimus su gyv\u016bnais, sunkaus \u0161alutinio poveikio nepasteb\u0117ta.<\/strong> arba toksi\u0161kumo veiksmingomis SLU-PP-332 doz\u0117mis. Pel\u0117ms, kurios buvo gydomos kelet\u0105 savai\u010di\u0173, pager\u0117jo \u012fvair\u016bs sveikatos rodikliai, be akivaizd\u017eios \u017ealos. Nors tai teikia vil\u010di\u0173, tai toli gra\u017eu n\u0117ra saugumo garantija \u017emon\u0117ms. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Svarbiausias apribojimas yra tiesiog <strong>ilgalaiki\u0173 duomen\u0173 apie poveik\u012f \u017emon\u0117ms tr\u016bkumas<\/strong>. Neai\u0161ku, kaip ilgalaikis ERR\u03b1 aktyvavimas gali paveikti \u012fvairius organus per ilg\u0105 laik\u0105. Pavyzd\u017eiui, nors ERR\u03b1 aktyvavimas skatina med\u017eiag\u0173 apykait\u0105 (tai naudinga na\u0161umui ir riebal\u0173 deginimui), pernelyg aktyvi med\u017eiag\u0173 apykaita gali sukelti tam tikr\u0173 audini\u0173 stres\u0105 arba sutrikdyti hormon\u0173 pusiausvyr\u0105 b\u016bdais, kuri\u0173 dar nesuprantame.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kadangi yra <strong>n\u0117ra SLU-PP-332 tyrim\u0173 su \u017emon\u0117mis.<\/strong>d\u0117l galimo \u0161alutinio poveikio turime pasikliauti neoficialiais \u012frodymais ir naudotoj\u0173 prane\u0161imais. Reddit tinkle, taip pat kituose \u0161altiniuose yra daug prane\u0161im\u0173 su naudotoj\u0173 patirtimi, kuriuose minimi keli i\u0161 j\u0173:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>K\u016bno temperat\u016bros (nedidelis) padid\u0117jimas ma\u017edaug 30 minu\u010di\u0173 po doz\u0117s pavartojimo. <\/strong><\/li>\n\n\n\n<li><strong>Tam tikras i\u0161sekimo lygis po pradinio energijos padid\u0117jimo. <\/strong><\/li>\n\n\n\n<li><strong>Padid\u0117j\u0119s prakaitavimas dirbant. <\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">N\u0117 vienas i\u0161 \u0161i\u0173 galim\u0173 \u0161alutini\u0173 poveiki\u0173 n\u0117ra \u0161okiruojantis ir toks, kokio b\u016bt\u0173 galima tik\u0117tis, atsi\u017evelgiant \u012f su \u0161iuo konkre\u010diu junginiu susijus\u012f veikimo b\u016bd\u0105.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">Kas domisi SLU-PP-332?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Nepaisant ankstyvosios stadijos, SLU-PP-332 suk\u0117l\u0117 susidom\u0117jim\u0105 keliuose sluoksniuose:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Akademiniai tyr\u0117jai<\/strong> tiria med\u017eiag\u0173 apykaitos sutrikimus, fizinio aktyvumo biologij\u0105 ir sen\u0117jim\u0105.<\/li>\n\n\n\n<li><strong>Biohakeriai<\/strong> i\u0161tirti naujas na\u0161umo ir atsigavimo galimybes (nors ir per anksti).<\/li>\n\n\n\n<li><strong>Vaist\u0173 k\u016br\u0117jai<\/strong> fizinio aktyvumo mimetik\u0173, kaip l\u0117tini\u0173 lig\u0173 gydymo priemoni\u0173, svarstymas.<\/li>\n\n\n\n<li><strong>Sportininkai ir treneriai<\/strong>, nors j\u0173 naudojimas sporte teb\u0117ra spekuliatyvus ir eti\u0161kai pavojingas.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Dozavimas ir vartojimas<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Tyrim\u0173 rezultatai<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Kadangi SLU-PP-332 \u0161iuo metu yra mokslini\u0173 tyrim\u0173 junginys, n\u0117ra standartizuotos \"doz\u0117s\" ar naudojimo protokolo \u017emon\u0117ms. Ta\u010diau supratimas, kaip jis buvo naudojamas tyrimuose, suteikia tam tikr\u0173 \u012f\u017evalg\u0173. Atliekant eksperimentus su gyv\u016bnais, <strong>santykinai didel\u0117s doz\u0117s<\/strong> reik\u0117jo pamatyti dramati\u0161k\u0105 poveik\u012f. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u012eprastas re\u017eimas pel\u0117ms buvo apie <strong>50 mg vienam kilogramui k\u016bno svorio, du kartus per par\u0105<\/strong> per kelias savaites. 70 kg sverian\u010diam \u017emogui analogi\u0161ka doz\u0117 b\u016bt\u0173 labai didel\u0117 (keli gramai per dien\u0105) - daug didesn\u0117, nei prakti\u0161kai kas nors gal\u0117t\u0173 suvartoti. Tik\u0117tina, kad jei SLU-PP-332 kada nors bus bandomas su \u017emon\u0117mis, veiksmingos doz\u0117s bus daug ma\u017eesn\u0117s, atsi\u017evelgiant \u012f med\u017eiag\u0173 apykaitos skirtumus ir didel\u012f junginio stiprum\u0105 (junginys aktyvuoja ERR\u03b1 esant nanomolinei koncentracijai).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kalbant apie <strong>administracija<\/strong>, ankstyvuosiuose tyrimuose SLU-PP-332 da\u017enai buvo \u0161virk\u0161\u010diamas. Pavyzd\u017eiui, mokslinink\u0173 grup\u0117s prane\u0161\u0117, kad junginys buvo \u0161virk\u0161\u010diamas pel\u0117ms (intraperitoni\u0161kai), siekiant u\u017etikrinti nuosekli\u0105 absorbcij\u0105. K\u016br\u0117jai atkreip\u0117 d\u0117mes\u012f \u012f poreik\u012f <strong>patobulinti jungin\u012f iki geriam\u0173j\u0173 table\u010di\u0173 formos.<\/strong>, nes \u017emon\u0117ms b\u016bt\u0173 geriau vartoti lengvai vartojamas tabletes. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Biologinis prieinamumas <\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Atrodo, kad SLU-PP-332 turi <strong>labai geras geriamasis biologinis prieinamumas (~45%)<\/strong> grau\u017eik\u0173 modeliuose, o tai rei\u0161kia, kad beveik pus\u0117 geriamosios doz\u0117s gali patekti \u012f krauj\u0105 - tai \u017eenklas, kad geriamoji doz\u0117 gali b\u016bti perspektyvi. To paties tyrimo metu nustatyta, kad grau\u017eik\u0173 organizme junginio pusin\u0117s eliminacijos laikas yra ma\u017edaug 8-10 valand\u0173, o tai rei\u0161kia, kad b\u016bsimiems vartotojams gali prireikti <strong>Dozavimas du kartus per dien\u0105<\/strong> i\u0161laikyti pastov\u0173 lyg\u012f.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kadangi nebuvo atlikti tyrimai su \u017emon\u0117mis, neai\u0161ku, ar biologinis prieinamumas \u017emon\u0117ms yra toks pat kaip grau\u017eikams. Tokie veiksniai kaip skrand\u017eio turinio buvimas ar nebuvimas gali tur\u0117ti \u012ftakos \u0161io junginio veiksmingumui, kai jis vartojamas per burn\u0105. D\u0117l \u0161ios prie\u017easties, <strong>kai kurie vartotojai pageidauja vartoti SLU-PP-332 po lie\u017euviu<\/strong>.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Anekdotiniai \u012frodymai ir vartotoj\u0173 ataskaitos <\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Kaip min\u0117jome anks\u010diau, SLU-PP-332 dar nebuvo tiriamas \u017emon\u0117ms. Tai nesustabd\u0117 fitneso, kult\u016brizmo ir biohakingo bendruomeni\u0173 nari\u0173 nuo \u0161io nuostabaus junginio tyrim\u0173, siekiant pagerinti jo veikim\u0105. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Daugyb\u0117 vartotoj\u0173 atsiliepim\u0173 apie SLU-PP-332 yra prieinami \u201eReddit\u201c, \u201eYouTube\u201c ir kitose platformose. \u0160ie neoficial\u016bs atsiliepimai suteikia \u012f\u017evalg\u0173 apie dozes, naudojamas savaranki\u0161ko eksperimentavimo praktikoje.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Prane\u0161ta apie dozavimo praktik\u0105<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Vartotojai nurodo \u012fvairias dozes, da\u017enai matuojamas mikrogramais (mcg):<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ma\u017eos doz\u0117s (250\u2013500 mcg\/dien\u0105):<\/strong> Kai kurie asmenys pradeda nuo 250 mcg ryte ir papildom\u0173 250 mcg prie\u0161 popietines treniruotes. \u0160is re\u017eimas yra \u017einomas d\u0117l i\u0161tverm\u0117s ir energijos lygio didinimo be \u017eymi\u0173 \u0161alutini\u0173 poveiki\u0173.<\/li>\n\n\n\n<li><strong>Vidutin\u0117s doz\u0117s (500-1000 mcg per dien\u0105):<\/strong> Kiti didina doz\u0119 iki 500 mkg du kartus per par\u0105 ir pastebi, kad nuolat ma\u017e\u0117ja riebal\u0173 kiekis ir pakyla k\u016bno temperat\u016bra. Ta\u010diau kai kurie prane\u0161a apie miego sutrikimus vartojant tok\u012f kiek\u012f. <\/li>\n\n\n\n<li><strong>Didel\u0117s doz\u0117s (1000-2000 mcg per dien\u0105):<\/strong> Dalis vartotoj\u0173 eksperimentuoja su iki 2000 mcg doz\u0117mis per par\u0105, kurias da\u017enai paskirsto ryte ir vakare. \u0160ie asmenys da\u017enai prane\u0161a apie ry\u0161k\u0173 poveik\u012f riebal\u0173 apykaitai ir energijai, ta\u010diau taip pat \u012fsp\u0117ja apie galim\u0105 perd\u0117t\u0105 stimuliacij\u0105.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Prane\u0161ta nauda<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">I\u0161 neoficialios patirties galima spr\u0119sti apie kelet\u0105 galim\u0173 privalum\u0173:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Daugiau energijos:<\/strong> Da\u017enai minimas padid\u0117j\u0119s energijos lygis ir suma\u017e\u0117j\u0119s jau\u010diamas kr\u016bvis treniruo\u010di\u0173 metu.<\/li>\n\n\n\n<li><strong>Padidinta i\u0161tverm\u0117:<\/strong> Vartotojai pastebi, kad pager\u0117jo i\u0161tverm\u0117 per \u0161irdies ir kraujagysli\u0173 bei pasiprie\u0161inimo treniruotes.<\/li>\n\n\n\n<li><strong>Riebal\u0173 netekimas:<\/strong> Kai kurie prane\u0161a apie greitesn\u012f riebal\u0173 kiekio ma\u017einim\u0105, ypa\u010d kai kartu su dietomis, kuri\u0173 metu kontroliuojamas kalorij\u0173 kiekis.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Prane\u0161ta apie \u0161alutin\u012f poveik\u012f<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Remiantis tais pa\u010diais naudotoj\u0173 prane\u0161imais, prane\u0161ta apie \u0161alutin\u012f poveik\u012f:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Padid\u0117j\u0119s prakaitavimas<\/strong><\/li>\n\n\n\n<li><strong>Nemiga<\/strong> (ypa\u010d vartojant didesnes dozes)<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">SLU-PP-332 teisinis statusas<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Kaip jau min\u0117jome, SLU-PP-332 yra labai ankstyvoje mokslini\u0173 tyrim\u0173 stadijoje. Jis n\u0117ra pripa\u017eintas kaip <strong>receptinis vaistas<\/strong> arba <strong>patvirtintas terapinis<\/strong> bet kurioje \u0161alyje, tod\u0117l jo prieinamumas ir teis\u0117tumas labai skiriasi priklausomai nuo jurisdikcijos.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">D\u0117l to, kad jo nepatvirtino tokios reguliavimo agent\u016bros kaip FDA ir EMA, jo negalima teis\u0117tai parduoti kaip maisto papildo, taip pat jo negalima i\u0161ra\u0161yti tradiciniais medicinos kanalais.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ra\u0161ymo metu SLU-PP-332 yra <strong>dar ne\u012ftraukta \u012f draud\u017eiam\u0173 med\u017eiag\u0173 s\u0105ra\u0161\u0105<\/strong> WADA ar bet kurio kito susijusio instituto. Kadangi \u0161is preparatas veikia riebal\u0173 apykait\u0105, jis gali b\u016bti \u012ftrauktas \u012f WADA draud\u017eiam\u0173 med\u017eiag\u0173 s\u0105ra\u0161\u0105, kai bus oficialiai patvirtintas jo poveikis rezultat\u0173 gerinimui. <\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Kur galiu \u012fsigyti SLU-PP-332 internetu?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Jei norite, labai svarbu rasti patikim\u0105 \u0161altin\u012f. <a href=\"https:\/\/hqsarms.com\/lt\/produktas\/slu-pp-332-liquid\/\" data-type=\"product\" data-id=\"15459\">pirkti SLU-PP-332<\/a> Europoje. Pasirinkdami <strong>patikimas tiek\u0117jas<\/strong> kokyb\u0117s, pristatymo ir palaikymo, galite i\u0161vengti nereikalingos rizikos. HQSARMS yra <strong>patikimas liquid, SARMs ir susijusi\u0173 mokslini\u0173 tyrim\u0173 chemini\u0173 med\u017eiag\u0173 tiek\u0117jas nuo 2019 m.<\/strong>, aptarnaujanti t\u016bkstan\u010dius klient\u0173 visoje Europoje. <\/p>\n\n\n\n<figure class=\"wp-block-image size-medium\"><a href=\"https:\/\/hqsarms.com\/lt\/produktas\/slu-pp-332-liquid\/\"><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/03\/slu-pp-332-bottle-small-300x300.png\" alt=\"SLU-PP-332 | Pirkti SLU-PP-332 liquid 1000mcg\/ml 30ml | HQSARMS\" class=\"wp-image-15460\" srcset=\"https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/03\/slu-pp-332-bottle-small-300x300.png 300w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/03\/slu-pp-332-bottle-small-150x150.png 150w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/03\/slu-pp-332-bottle-small-12x12.png 12w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/03\/slu-pp-332-bottle-small-441x441.png 441w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/03\/slu-pp-332-bottle-small-100x100.png 100w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/03\/slu-pp-332-bottle-small-600x600.png 600w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/03\/slu-pp-332-bottle-small.png 750w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/a><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Pirkdami SLU-PP-332 i\u0161 HQSARMS, gausite kelet\u0105 privalum\u0173:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Kokyb\u0117s u\u017etikrinimas:<\/strong> M\u016bs\u0173 product produktai yra ne ma\u017eiau kaip 98% grynumo, o dozavimo skirtumas tarp partij\u0173 yra ma\u017eesnis nei 5%. <\/li>\n\n\n\n<li><strong>Garantuotas pristatymas:<\/strong> Jei pateiksite galiojant\u012f pristatymo adres\u0105, garantuojame, kad j\u016bs\u0173 siuntinys bus pristatytas, arba gr\u0105\u017einsime vis\u0105 sum\u0105.  <\/li>\n\n\n\n<li><strong>Didel\u0117 doz\u0117: <\/strong>HQSARMS SLU-PP-332 liquid doz\u0117 yra 1000 mcg (arba 1 mg) viename mililitre, o dauguma pardav\u0117j\u0173 j\u012f parduoda 250 mcg\/ml koncentracijos. <\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Da\u017eniausiai u\u017eduodami klausimai<a href=\"https:\/\/en.wikipedia.org\/wiki\/SLU-PP-332#:~:text=,6\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/h2>\n\n\n<div id=\"rank-math-faq\" class=\"rank-math-block\">\n<div class=\"rank-math-list\">\n<div id=\"faq-question-1747783419310\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Koks yra SLU-PP-332 biologinis prieinamumas per burn\u0105?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Tyrimai su grau\u017eikais parod\u0117, kad SLU-PP-332 biologinis prieinamumas yra apie 45%.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1747783608789\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Ar SLU-PP-332 turi \u012ftakos estrogen\u0173 kiekiui?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Ne. Tai, kad \u0161is junginys yra <strong>su estrogenais susijusi\u0173 receptori\u0173 agonistas<\/strong> (ERR\u03b1 \/ ERR\u03b3) nerei\u0161kia, kad jis turi \u012ftakos estrogen\u0173 kiekiui. <\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1747783836562\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Ar SLU-PP-332 yra teis\u0117tas?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Kaip ir daugumos kit\u0173 mokslini\u0173 tyrim\u0173 chemini\u0173 med\u017eiag\u0173, FDA ar bet kuri kita reguliavimo agent\u016bra n\u0117ra patvirtinusi, kad j\u0105 galima vartoti \u017emon\u0117ms. Tai i\u0161 esm\u0117s rei\u0161kia, kad <strong>jis teis\u0117tas tik tada, kai parduodamas mokslini\u0173 tyrim\u0173 tikslais.<\/strong>. <\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1757882864246\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Ar SLU-PP-332 yra peptidas?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Ne, <strong>SLU-PP-332 i\u0161 tikr\u0173j\u0173 n\u0117ra peptidas<\/strong>, bet ma\u017eos molekul\u0117s ERR (su estrogenais susijusi\u0173 receptori\u0173) agonistas. Peptidai yra aminor\u016bg\u0161\u010di\u0173 grandin\u0117s, sujungtos peptidin\u0117mis jungtimis, o SLU tokios strukt\u016bros neturi.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1762116553082\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Kokia SLU-PP-332 doz\u0117 per dien\u0105 yra standartin\u0117?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Remiantis neoficialiais duomenimis ir vartotoj\u0173 ataskaitomis, da\u017eniausiai vartojama SLU-PP-332 doz\u0117 yra nuo 250 mcg iki 1000 mcg per dien\u0105. \u0160iam junginiui n\u0117ra nustatyta faktin\u0117 standartin\u0117 paros doz\u0117, nes jis dar n\u0117ra i\u0161bandytas klinikiniais tyrimais su \u017emon\u0117mis. <\/p>\n\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">Nuorodos<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Billon, C., et al. (2023).<\/strong> \u201c<a href=\"https:\/\/collections.uhsp.edu\/pharm-admin-sciences_pubs\/44\/\" target=\"_blank\" data-schema-attribute=\"about mentions\" rel=\"noreferrer noopener\">Sintetinis ERR agonistas palengvina metabolin\u012f sindrom\u0105.<\/a>\u201d <em>Journal of Pharmacology and Experimental Therapeutics.<\/em><\/li>\n\n\n\n<li><strong>Billon, C., et al. (2022).<\/strong> \u201c<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36988910\/\" target=\"_blank\" data-schema-attribute=\"about mentions\" rel=\"noreferrer noopener\">Sintetinis ERR\u03b1\/\u03b2\/\u03b3 agonistas sukelia nuo ERR\u03b1 priklausom\u0105 \u016bmin\u0119 aerobini\u0173 pratim\u0173 program\u0105.<\/a>\u201d <em>ACS Chemical Biology.<\/em><\/li>\n\n\n\n<li><strong>Nasri, H. (2024).<\/strong> \u201c<a href=\"https:\/\/www.jrenendo.com\/PDF\/jre-10-e25143.pdf\" target=\"_blank\" data-schema-attribute=\"about mentions\" rel=\"noreferrer noopener\">Naujos viltys d\u0117l \"SLU-PP-332\" kaip veiksmingos svorio ma\u017einimo priemon\u0117s, turin\u010dios netiesiogin\u012f inkst\u0173 apsaugos veiksmingum\u0105; nefrologijos po\u017ei\u016briu.<\/a>\u201d <em>Journal of Renal Endocrinology.<\/em><\/li>\n\n\n\n<li><strong>Elgendy, B. ir kt. (2024).<\/strong> \u201c<a href=\"https:\/\/fortune.com\/well\/2024\/03\/18\/exercise-mimicking-pill\/\" target=\"_blank\" data-schema-attribute=\"about mentions\" rel=\"noreferrer noopener\">Treniruo\u010di\u0173 tablet\u0117s netrukus gali suteikti toki\u0105 pa\u010di\u0105 naud\u0105 kaip ir treniruot\u0117s.<\/a>\u201d <em>\"Fortune Well\".<\/em><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>Imagine getting the benefits of exercise: better endurance, enhanced metabolism, and improved fat-burning, without ever picking up a dumbbell or lacing up your running shoes. While that might sound like science fiction, researchers at Saint Louis University have identified a compound that moves us closer to that reality. Meet SLU-PP-332, a novel compound that mimics [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":15892,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_eb_attr":"","iawp_total_views":7044,"footnotes":""},"categories":[17],"tags":[],"class_list":["post-15881","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sarms"],"_links":{"self":[{"href":"https:\/\/hqsarms.com\/lt\/wp-json\/wp\/v2\/posts\/15881","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hqsarms.com\/lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hqsarms.com\/lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hqsarms.com\/lt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hqsarms.com\/lt\/wp-json\/wp\/v2\/comments?post=15881"}],"version-history":[{"count":1,"href":"https:\/\/hqsarms.com\/lt\/wp-json\/wp\/v2\/posts\/15881\/revisions"}],"predecessor-version":[{"id":19506,"href":"https:\/\/hqsarms.com\/lt\/wp-json\/wp\/v2\/posts\/15881\/revisions\/19506"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hqsarms.com\/lt\/wp-json\/wp\/v2\/media\/15892"}],"wp:attachment":[{"href":"https:\/\/hqsarms.com\/lt\/wp-json\/wp\/v2\/media?parent=15881"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hqsarms.com\/lt\/wp-json\/wp\/v2\/categories?post=15881"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hqsarms.com\/lt\/wp-json\/wp\/v2\/tags?post=15881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}